ABBV241011P200000
- 6.47
- 0.000.00%
AbbVie Newsroom
Nano-Cap Bio-Path Takes Plunge In Weight Loss Race, Initiates Obesity Program With Drug Candidate Under Development For Blood Cancer
TD Cowen Maintains AbbVie(ABBV.US) With Buy Rating, Raises Target Price to $225
In-Depth Examination Of 11 Analyst Recommendations For AbbVie
AbbVie Is Maintained at Buy by TD Cowen
AbbVie Analyst Ratings
AbbVie Insiders Sell US$56m Of Stock, Possibly Signalling Caution
Express News | Abbvie : TD Cowen Raises Target Price to $225 From $195
Wall Street's Most Accurate Analysts Spotlight On 3 Health Care Stocks Delivering High-Dividend Yields
Barclays Maintains AbbVie(ABBV.US) With Buy Rating, Maintains Target Price $212
AbbVie (ABBV) Gets a Buy From Barclays
Barclays Adjusts Price Target on AbbVie to $212 From $200, Maintains Overweight Rating
AbbVie's Atogepant Set to Reach Projected Worth of $766m in 2026 After Accepted NDA From FDA
Morgan Stanley Maintains AbbVie(ABBV.US) With Buy Rating, Maintains Target Price $218
Allergan Aesthetics and Girls Inc. Celebrate Six Years and Challenge You to Take the Pledge to Support Mentorship in STEM
AbbVie (ABBV) Suffers a Larger Drop Than the General Market: Key Insights
AbbVie Cuts Q3, FY Adj. EPS Outlook
AbbVie Cuts 2024 Profit Forecast on R&D Expenses
Express News | Abbvie: Reported Gaap & Adjusted Non-Gaap Earnings for Q3 Expected to Include Acquired Ipr&D & Milestones Expense of $82 Mln on Pre-Tax Basis
Blue Shield of California Slashes Humira Biosimilar Prices in Landmark Deal
Comparing AbbVie With Industry Competitors In Biotechnology Industry